Sangamo launches auction for ST-503 pain program as Chapter 11 asset sales close with $163.55 million proceeds

Bitget2026/10/13 20:01

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Sangamo set a fourth-quarter 2026 deadline for an auction of its clinical-stage ST-503 chronic neuropathic pain program.
Asset sales completed through a court-supervised Section 363 process generated USD 163.55 million in gross cash proceeds.
PTC bought the Fabry disease program ST-920 for USD 111 million in cash, with up to USD 100 million in milestone payments.
Lilly acquired Sangamo’s capsid delivery, zinc finger and MINT platforms, with the ST-506 prion disease program, for USD 50 million in cash.
Proceeds were used to repay all outstanding amounts under the debtor-in-possession financing facility provided by Future Solutions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sangamo Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610131601PRIMZONEFULLFEED9844823) on October 13, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Sangamo launches auction for ST-503 pain program as Chapter 11 asset sales close with $163.55 million proceeds

You may also like

Crypto prices